KR20200113429A - Composition for enhancing bioavailability of silymarin - Google Patents
Composition for enhancing bioavailability of silymarin Download PDFInfo
- Publication number
- KR20200113429A KR20200113429A KR1020190033602A KR20190033602A KR20200113429A KR 20200113429 A KR20200113429 A KR 20200113429A KR 1020190033602 A KR1020190033602 A KR 1020190033602A KR 20190033602 A KR20190033602 A KR 20190033602A KR 20200113429 A KR20200113429 A KR 20200113429A
- Authority
- KR
- South Korea
- Prior art keywords
- silymarin
- oil
- bioavailability
- improving
- composition
- Prior art date
Links
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 title claims abstract description 95
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 title claims abstract description 95
- 235000017700 silymarin Nutrition 0.000 title claims abstract description 88
- 229960004245 silymarin Drugs 0.000 title claims abstract description 88
- 239000000203 mixture Substances 0.000 title claims abstract description 85
- 230000002708 enhancing effect Effects 0.000 title abstract 6
- 235000013305 food Nutrition 0.000 claims abstract description 31
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 25
- 239000000787 lecithin Substances 0.000 claims abstract description 25
- 235000010445 lecithin Nutrition 0.000 claims abstract description 25
- 229940067606 lecithin Drugs 0.000 claims abstract description 25
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims abstract description 23
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 12
- 239000008158 vegetable oil Substances 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 239000000654 additive Substances 0.000 claims description 28
- 230000000996 additive effect Effects 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 20
- 229940096421 milk thistle extract Drugs 0.000 claims description 16
- 235000020727 milk thistle extract Nutrition 0.000 claims description 16
- 238000009472 formulation Methods 0.000 claims description 11
- 238000010828 elution Methods 0.000 claims description 10
- 239000007901 soft capsule Substances 0.000 claims description 10
- 238000007922 dissolution test Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000008213 purified water Substances 0.000 claims description 5
- 239000003549 soybean oil Substances 0.000 claims description 5
- 235000012424 soybean oil Nutrition 0.000 claims description 5
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 4
- 235000019482 Palm oil Nutrition 0.000 claims description 4
- 239000002540 palm oil Substances 0.000 claims description 4
- 229940083466 soybean lecithin Drugs 0.000 claims description 4
- 235000019486 Sunflower oil Nutrition 0.000 claims description 3
- 235000005687 corn oil Nutrition 0.000 claims description 3
- 239000002285 corn oil Substances 0.000 claims description 3
- 235000012343 cottonseed oil Nutrition 0.000 claims description 3
- 239000002385 cottonseed oil Substances 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 235000019198 oils Nutrition 0.000 claims description 3
- 239000002600 sunflower oil Substances 0.000 claims description 3
- 235000019489 Almond oil Nutrition 0.000 claims description 2
- 235000019487 Hazelnut oil Nutrition 0.000 claims description 2
- 235000019483 Peanut oil Nutrition 0.000 claims description 2
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 2
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 2
- 244000000231 Sesamum indicum Species 0.000 claims description 2
- 235000019498 Walnut oil Nutrition 0.000 claims description 2
- 239000008168 almond oil Substances 0.000 claims description 2
- 239000008163 avocado oil Substances 0.000 claims description 2
- 235000021302 avocado oil Nutrition 0.000 claims description 2
- 235000021329 brown rice Nutrition 0.000 claims description 2
- 239000000828 canola oil Substances 0.000 claims description 2
- 235000019519 canola oil Nutrition 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 210000002969 egg yolk Anatomy 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000008169 grapeseed oil Substances 0.000 claims description 2
- 239000010468 hazelnut oil Substances 0.000 claims description 2
- 239000000944 linseed oil Substances 0.000 claims description 2
- 235000021388 linseed oil Nutrition 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 239000000312 peanut oil Substances 0.000 claims description 2
- 239000008170 walnut oil Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 8
- 239000003960 organic solvent Substances 0.000 abstract description 6
- 230000000052 comparative effect Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 11
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- VLGROHBNWZUINI-UHFFFAOYSA-N Silybin Natural products COc1cc(ccc1O)C2OC3C=C(C=CC3OC2CO)C4Oc5cc(O)cc(O)c5C(=O)C4O VLGROHBNWZUINI-UHFFFAOYSA-N 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 229940043175 silybin Drugs 0.000 description 7
- 235000014899 silybin Nutrition 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 235000010841 Silybum marianum Nutrition 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 208000019423 liver disease Diseases 0.000 description 6
- 241000320380 Silybum Species 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 244000272459 Silybum marianum Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940068965 polysorbates Drugs 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- -1 silicistin Chemical compound 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- FDQAOULAVFHKBX-KMRPREKFSA-N (+)-Isosilybin A Natural products C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC(=CC=C3O2)[C@@H]2[C@@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-KMRPREKFSA-N 0.000 description 1
- FDQAOULAVFHKBX-HKTJVKLFSA-N (2r,3r)-3,5,7-trihydroxy-2-[(2r,3r)-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydrochromen-4-one Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC(=CC=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-HKTJVKLFSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000132536 Cirsium Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- KDMGQPNVTKUNHV-UHFFFAOYSA-N Isosilybin Natural products C1=C(O)C(OC)=CC=C1C1C(CO)OC2=CC=C(C3C(C(=O)C4=C(O)C=C(O)C=C4O3)O)C=C2O1 KDMGQPNVTKUNHV-UHFFFAOYSA-N 0.000 description 1
- CYGIJEJDYJOUAN-UHFFFAOYSA-N Isosilychristin Natural products C1=C(O)C(OC)=CC(C2C3C=C(C4C(C3=O)(O)OCC42)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 CYGIJEJDYJOUAN-UHFFFAOYSA-N 0.000 description 1
- MZBGBHVFCYCYLX-UHFFFAOYSA-N Silydianin Natural products COc1cc(ccc1O)C2C3COC4(O)C3C=C(C5Oc6cc(O)cc(O)c6C(=O)C5O)C2C4=O MZBGBHVFCYCYLX-UHFFFAOYSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- CYGIJEJDYJOUAN-JSGXPVSSSA-N silydianin Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@H]3C=C([C@@H]4[C@@](C3=O)(O)OC[C@@H]42)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 CYGIJEJDYJOUAN-JSGXPVSSSA-N 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
- A23L29/04—Fatty acids or derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
- A23P10/35—Encapsulation of particles, e.g. foodstuff additives with oils, lipids, monoglycerides or diglycerides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/184—Emulsifier
- A23V2250/1842—Lecithin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/184—Emulsifier
- A23V2250/1846—Phosphatidyl Choline
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 실리마린의 생체이용률 향상용 첨가제 조성물 및 이를 포함하는 식품 조성물에 관한 것이다.The present invention relates to an additive composition for improving the bioavailability of silymarin and a food composition comprising the same.
실리마린은 국화과에 속하는 약용식물인 카르두스 마리아누스(Carduus marianus Linne(Silybum mariannum))의 학명을 가진 마리아 엉겅퀴에서 추출한 성분으로서, 플라보노이드(flavonoid)계 화합물의 일종이다. 이 식물은 남유럽과 북아프리카가 원산지이나 이후에 아메리카 대륙에도 정착하여 현재는 관상용이나 약용으로 재배되고 있다.Silymarin is a component extracted from Maria Thistle, which has the scientific name of Carduus marianus Linne (Silybum mariannum), a medicinal plant belonging to the Asteraceae family, and is a kind of flavonoid-based compound. This plant was native to Southern Europe and North Africa, but later settled in the Americas and is now cultivated for ornamental or medicinal purposes.
실리마린은 간세포막을 안정화시켜 유해물질의 세포 내 유입을 억제하며, 간세포의 단백질 합성을 활성화시켜 간세포의 재생을 촉진시킨다는 것이 알려져 있어, 흡연, 음주, 과로 및 각종 공해에 의한 환경오염 등으로 인하여 발병되는 다양한 간질환 치료에 널리 응용되고 있다.Silymarin is known to stabilize the liver cell membrane to inhibit the influx of harmful substances into the cell, and to promote the regeneration of hepatocytes by activating the protein synthesis of hepatocytes.It is caused by smoking, alcohol, overwork, and environmental pollution caused by various pollution. It is widely applied to the treatment of various liver diseases.
실리마린을 유효성분으로 함유하는 제제의 경우 이미 임상적으로 간절환 치료에 널리 응용되고 있지만, 그 유효성분인 실리마린은 물에 거의 녹지 않는 난용성 물질로서 경구 투여 시 체내 흡수율이 낮아 생체이용률이 약 20~40%에 불과하다. 따라서 용해성 및 용출율을 증가시켜 생체이용률을 향상시키는 것이 실리마린 함유 제제의 개발에 있어서 중요하다고 할 수 있다.In the case of formulations containing silymarin as an active ingredient, it has already been widely applied clinically for liver switching treatment, but silymarin, the active ingredient, is a poorly soluble substance that is hardly soluble in water and has a low absorption rate in the body when administered orally, resulting in a bioavailability of about 20 It is only ~40%. Therefore, it can be said that improving the bioavailability by increasing the solubility and dissolution rate is important in the development of silymarin-containing formulations.
종래에는 실리마린의 낮은 용해도 및 생체이용률을 향상시키기 위하여 약물, 오일, 계면활성제, 공계면활성제, 용제 등으로 이루어진 자가유화전달 시스템(self-emulsifying drug delivery system)을 적용하였으나, 이 경우 다량의 합성 계면활성제(예를 들어, 폴리소르베이트류 등)와 식품용이 아닌 유기 용매(예를 들어, 헥산 등)를 다량 사용함으로 인해 위염이나 위궤양 같은 위장장애가 있는 사용자에게 더 자극을 주거나, 설사, 복통 등을 일으키는 등의 부작용을 유발할 뿐만 아니라, 제제의 부피가 커져서 복용하기 불편하다는 단점이 있었다.Conventionally, in order to improve the low solubility and bioavailability of silymarin, a self-emulsifying drug delivery system consisting of drugs, oils, surfactants, co-surfactants, and solvents has been applied, but in this case, a large amount of synthetic interface The use of large amounts of active agents (eg, polysorbates, etc.) and non-food organic solvents (eg, hexane, etc.) may further irritate users with gastrointestinal disorders such as gastritis or gastric ulcers, or reduce diarrhea and abdominal pain. In addition to causing side effects such as causing, there is a disadvantage that it is inconvenient to take because the volume of the formulation is increased.
또한, 실리마린을 정제(tablet)로 섭취하는 경우에는 특유의 냄새 등으로 인하여 소비자 선호도가 떨어지는 이유로 연질캡슐에 대한 요구가 있으며, 복용 편의성의 측면에서 작은 크기에 고함량의 기능성분을 포함하는 기술이 요구되고 있다.In addition, when silymarin is ingested as a tablet, there is a demand for soft capsules due to the low consumer preference due to its peculiar smell, and in terms of ease of use, a technology containing a high content of functional ingredients in a small size is not Is required.
본 발명은 상기한 문제점을 해결하기 위하여, 합성계면활성제를 포함하지 않아 부작용을 나타내지 않으면서도 실리마린의 용해도와 생체이용률을 효과적으로 향상시키는 실리마린의 생체이용률 향상용 첨가제 조성물, 및 상기 실리마린의 생체이용률 향상용 첨가제 조성물을 포함하여 우수한 실리마린의 생체이용률을 나타내는 식품 조성물을 제공하는 것을 목적으로 한다.In order to solve the above problems, the present invention is an additive composition for improving the bioavailability of silymarin, which effectively improves the solubility and bioavailability of silymarin without showing side effects since it does not contain a synthetic surfactant, and for improving the bioavailability of silymarin. It is an object of the present invention to provide a food composition showing excellent bioavailability of silymarin, including an additive composition.
상기한 목적을 달성하기 위하여, 본 발명의 일 실시예는,In order to achieve the above object, an embodiment of the present invention,
실리마린의 생체이용률 향상용 첨가제 조성물로서,As an additive composition for improving the bioavailability of silymarin,
레시틴(lecithin) 및 포스파티딜콜린(phosphatidylcholine) 중 하나 이상을 유효성분으로 함유하며,It contains at least one of lecithin and phosphatidylcholine as an active ingredient,
실리마린 및 식물성 오일을 포함하는 식품 조성물에 첨가되고,It is added to a food composition comprising silymarin and vegetable oil,
상기 실리마린 : 레시틴 및 포스파티딜콜린 중 하나 이상의 중량비가 1:0.08 이상 및 1:2.31 미만이 되도록 상기 식품 조성물에 첨가되는, 실리마린의 생체이용률 향상용 첨가제 조성물을 제공한다.It provides an additive composition for improving the bioavailability of silymarin, which is added to the food composition so that the weight ratio of at least one of the silymarin: lecithin and phosphatidylcholine is 1:0.08 or more and 1:2.31 or less.
또한, 본 발명의 다른 실시예는,In addition, another embodiment of the present invention,
실리마린의 생체이용률 향상용 첨가제 조성물로서,As an additive composition for improving the bioavailability of silymarin,
레시틴(lecithin) 및 포스파티딜콜린(phosphatidylcholine) 중 하나 이상을 유효성분으로 함유하며,It contains at least one of lecithin and phosphatidylcholine as an active ingredient,
실리마린 및 식물성 오일을 포함하는 식품 조성물에 첨가되고,It is added to a food composition comprising silymarin and vegetable oil,
상기 식품 조성물은 대한민국약전에 의거한 용출시험법의 패들법에 따라 정제수에서 용출 시험 시, 240분 이내에 실리마린의 용출 농도가 6 내지 31 μg/mL인, 실리마린의 생체이용률 향상용 첨가제 조성물을 제공한다.The food composition provides an additive composition for improving the bioavailability of silymarin, wherein the elution concentration of silymarin is 6 to 31 μg/mL within 240 minutes when the dissolution test is performed in purified water according to the paddle method of the dissolution test method based on the Korean Pharmacopoeia. .
본 발명에 의한 실리마린의 생체이용률 향상용 첨가제 조성물은, 합성계면활성제를 포함하지 않으면서도 실리마린의 생체이용률을 효과적으로 향상시킬 수 있다.The additive composition for improving the bioavailability of silymarin according to the present invention can effectively improve the bioavailability of silymarin without containing a synthetic surfactant.
또한, 본 발명에 의한 실리마린의 생체이용률 향상용 첨가제 조성물을 포함하는 식품 조성물은, 합성계면활성제와 유기용매를 사용하지 않으면서 우수한 실리마린의 용해도와 생체이용률을 나타낼 수 있고 합성계면활성제 또는 유기용매 사용으로 인한 부작용 또한 방지할 수 있다.In addition, the food composition comprising the additive composition for improving the bioavailability of silymarin according to the present invention can exhibit excellent solubility and bioavailability of silymarin without using a synthetic surfactant and an organic solvent, and use a synthetic surfactant or an organic solvent. It can also prevent side effects caused by.
도 1은 실험예 1에 따른 용출율 실험 결과를 나타낸 것이다.
도 2는 실험예 2에 따른 붕해 시험 결과를 나타낸 것이다.
도 3은 실험예 3에 따른 생체이용률 실험 결과를 나타낸 것이다.1 shows the results of the dissolution rate experiment according to Experimental Example 1.
2 shows the results of the disintegration test according to Experimental Example 2.
3 shows the results of a bioavailability experiment according to Experimental Example 3.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 일 측면에서, 레시틴(lecithin) 및 포스파티딜콜린(phosphatidylcholine) 중 하나 이상을 유효성분으로 함유하는 실리마린의 생체이용률 향상용 첨가제 조성물에 관한 것일 수 있다.In one aspect, the present invention may relate to an additive composition for improving bioavailability of silymarin containing at least one of lecithin and phosphatidylcholine as an active ingredient.
상기 실리마린의 생체이용률 향상용 첨가제 조성물은 실리마린 및 식물성 오일을 포함하는 식품 조성물에 첨가될 수 있다.The additive composition for improving the bioavailability of silymarin may be added to a food composition including silymarin and vegetable oil.
상기 실리마린(silymarin)은 간세포막을 안정화시켜 유해물질의 세포 내 유입을 억제하며, 간세포의 단백질 합성을 활성화시켜 간세포의 재생을 촉진시킨다는 것이 알려져 있으며, 특히 강력한 항산화 작용을 가지며, 인지질 합성 감소, 중성지질의 과다축적 방지, 혈청 LDL 감소, 항염, 항암, 급성 바이러스성 간염, 만성 간염, 간경화 합병증 환자의 회복 촉진 작용을 갖는 것으로 알려져 흡연, 음주, 과로 및 각종 공해에 의한 환경오염 등으로 인하여 발병되는 다양한 간 질환의 치료에 널리 응용되고 있다.It is known that silymarin stabilizes the hepatocyte membrane to inhibit the influx of harmful substances into the cell, and promotes the regeneration of hepatocytes by activating the protein synthesis of hepatocytes.In particular, it has a strong antioxidant activity, decreases phospholipid synthesis, and reduces the synthesis of neutral lipids. It is known to have the effect of promoting recovery of patients with complications of liver cirrhosis, anti-inflammatory, anti-cancer, acute viral hepatitis, chronic hepatitis, and liver cirrhosis. It is widely applied in the treatment of diseases.
또한, 상기 실리마린은 주성분인 실리빈(Silybin), 실리빈의 이성질체인 실리크리스틴(Silicristin), 실리디아닌 (Silidianin) 및 이소실리빈(isosilybin) 등이 혼합되어 있는 플라보리그난(flavolignans)의 집합체이다.In addition, the silymarin is an aggregate of flavoignans in which silybin, an isomer of silybin, silicistin, silydianin, isosilybin, and the like are mixed. to be.
일 구현 예에 있어서, 상기 실리마린은 밀크씨슬(milk thistle) 추출물로부터 얻은 것일 수 있다. 이때, "밀크씨슬"은 Silybum marianum을 학명으로 하는 식물을 말하며, "밀크씨슬 추출물"은 밀크씨슬로부터 분리하여 얻은 물질을 의미하는 것으로, 구체적으로는 당업계에 공지된 통상적인 추출 용매, 예를 들어, 물, C1-C4 알코올(예를 들어, 메탄올, 에탄올, 부탄올 등), 또는 상기 알코올과 물의 혼합 용매 등을 사용하여 분리하여 밀크씨슬로부터 얻은 물질을 의미한다.In one embodiment, the silymarin may be obtained from milk thistle extract. At this time, "Milk Thistle" refers to a plant whose scientific name is Silybum marianum , and "Milk Thistle Extract" refers to a material obtained by separating from milk thistle, and specifically, a conventional extraction solvent known in the art , For example, refers to a substance obtained from milk thistle by separating using water, C1-C4 alcohol (eg, methanol, ethanol, butanol, etc.), or a mixed solvent of the alcohol and water.
또한, 상기 밀크씨슬 추출물은 공지된 다양한 추출 방법, 예컨대, 열수추출, 유기용매 추출 또는 초임계 추출 등을 이용하여 수득한 것일 수 있으며, 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조된 것일 수 있다.In addition, the milk thistle extract may be obtained by using various known extraction methods, such as hot water extraction, organic solvent extraction, or supercritical extraction, and by additional processes such as distillation under reduced pressure and freeze drying or spray drying. It may be prepared in a powder state.
일 구현 예에 있어서, 상기 레시틴은 대두레시틴 및 난황레시틴 중 하나 이상일 수 있다.In one embodiment, the lecithin may be at least one of soybean lecithin and yolk lecithin.
본 발명은 폴리소르베이트(polysorbate)류와 같은 합성계면활성제를 사용하지 않고 레시틴 및 포스파티딜콜린과 같은 천연계면활성제를 포함함으로써 합성계면활성제를 다량 함유함으로 인한 부작용을 나타내지 않을 수 있다.The present invention does not use synthetic surfactants such as polysorbates, but contains natural surfactants such as lecithin and phosphatidylcholine, so that side effects due to containing a large amount of synthetic surfactants may not be exhibited.
일 구현 예에 있어서, 상기 식물성 오일은 대두유, 해바라기유, 유채씨유, 아보카도유, 옥수수유(옥배유), 팜유, 야자유, 현미유, 목화씨유(면실유), 피마자유, 참깨씨유, 아마씨유, 올리브유, 카놀라유, 포도씨유, 아몬드유, 땅콩유, 헤이즐넛유 및 호두유 중에서 선택된 하나 이상일 수 있다.In one embodiment, the vegetable oil is soybean oil, sunflower oil, rapeseed oil, avocado oil, corn oil (corn oil), palm oil, palm oil, brown rice oil, cottonseed oil (cottonseed oil), castor oil, sesame seed oil, flaxseed oil, It may be one or more selected from olive oil, canola oil, grapeseed oil, almond oil, peanut oil, hazelnut oil, and walnut oil.
일 구현 예에 있어서, 상기 첨가제 조성물은, 실리마린 : 레시틴 및 포스파티딜콜린 중 하나 이상의 중량비가 1:0.08 이상 및 1:2.31 미만이 되도록 상기 식품 조성물에 첨가될 수 있다.In one embodiment, the additive composition may be added to the food composition such that a weight ratio of at least one of silymarin: lecithin and phosphatidylcholine is 1:0.08 or more and 1:2.31 or less.
다른 구현 예에 있어서, 상기 식품 조성물 내에서, 상기 실리마린 : 레시틴 및 포스파티딜콜린 중 하나 이상의 중량비는, 1:0.08 이상, 1:0.15 이상, 1:0.23 이상, 1:0.35 이상, 1:0.40 이상, 1:0.46 이상, 1:0.53 이상, 1:1 이상, 1:1.23 이상 또는 1:1.53 이상일 수 있으며, 또한, 상기 실리마린 : 레시틴 및 포스파티딜콜린 중 하나 이상의 중량비는, 1:2.31 미만, 1:2.3 이하, 1:2 이하, 1:1.7 이하, 1:1.53 이하, 1:1.4 이하, 1:1.23 이하, 1:1 이하, 1:0.7 이하, 1:0.53 이하 또는 1:0.46 이하일 수 있다. 바람직하게는, 상기 식품 조성물 내에서 상기 실리마린 : 레시틴 및 포스파티딜콜린 중 하나 이상의 중량비는, 1:0.46 내지 1:1.53일 수 있으며, 상기 범위에서 실리마린의 생체이용률이 보다 높게 나타날 수 있다.In another embodiment, in the food composition, the silymarin: at least one weight ratio of lecithin and phosphatidylcholine is 1:0.08 or more, 1:0.15 or more, 1:0.23 or more, 1:0.35 or more, 1:0.40 or more, 1 :0.46 or more, 1:0.53 or more, 1:1 or more, 1:1.23 or more, or 1:1.53 or more, and the silymarin: at least one weight ratio of lecithin and phosphatidylcholine is less than 1:2.31, less than 1:2.3, It may be 1:2 or less, 1:1.7 or less, 1:1.53 or less, 1:1.4 or less, 1:1.23 or less, 1:1 or less, 1:0.7 or less, 1:0.53 or less, or 1:0.46 or less. Preferably, the weight ratio of at least one of silymarin: lecithin and phosphatidylcholine in the food composition may be 1:0.46 to 1:1.53, and the bioavailability of silymarin may be higher in the above range.
일 구현 예에 있어서, 본 발명에 따른 식품 조성물은 연질캡슐 제형일 수 있다. 다른 구현 예에 있어서, 상기 식품 조성물은 유효 성분 이외에 해당 분야에서 통상적으로 사용되는 성분들을 연질캡슐 제형으로 제조하는 데 있어서 당업계의 통상의 기술자가 어려움 없이 적의 선정하여 배합할 수 있다.In one embodiment, the food composition according to the present invention may be a soft capsule formulation. In another embodiment, the food composition may be appropriately selected and blended without difficulty by a person skilled in the art in preparing a soft capsule formulation of ingredients commonly used in the field in addition to the active ingredient.
일 구현 예에 있어서, 상기 식품 조성물은 점도가 1800 cps 미만일 수 있다. 구체적으로, 상기 식품 조성물의 점도는 1800 cps 미만, 1600 cps 미만, 1400 cps 미만, 1200 cps 미만, 1000 cps 미만, 800 cps 미만, 600 cps 미만, 400 cps 미만 또는 200 cps 미만일 수 있으며, 또한, 10 cps 이상, 50 cps 이상, 100 cps 이상, 200 cps 이상, 400 cps 이상, 600 cps 이상, 800 cps 이상, 1000 cps 이상, 1200 cps 이상, 1400 cps 이상 또는 1600 cps 이상일 수 있다.In one embodiment, the food composition may have a viscosity of less than 1800 cps. Specifically, the viscosity of the food composition may be less than 1800 cps, less than 1600 cps, less than 1400 cps, less than 1200 cps, less than 1000 cps, less than 800 cps, less than 600 cps, less than 400 cps or less than 200 cps, and also 10 It may be cps or more, 50 cps or more, 100 cps or more, 200 cps or more, 400 cps or more, 600 cps or more, 800 cps or more, 1000 cps or more, 1200 cps or more, 1400 cps or more, or 1600 cps or more.
일 구현 예에 있어서, 상기 식품 조성물은 대한민국약전에 의거한 용출시험법의 패들법에 따라 정제수에서 용출 시험 시, 구체적으로, 정제수 500ml를 용출액으로 하여 37℃에서 회전수 150rpm으로 회전시켜 측정 시, 240분 이내에 실리마린의 용출 농도가 6 내지 31 μg/mL일 수 있다. 다른 구현 예에 있어서, 상기 실리마린의 용출 농도는, 6 μg/mL 이상, 6.5 μg/mL 이상, 7 μg/mL 이상, 8 μg/mL 이상, 8.5 μg/mL 이상, 9 μg/mL 이상, 9.5 μg/mL 이상, 15 μg/mL 이상, 19 μg/mL 이상, 19.6 μg/mL 이상, 23μg/mL 이상, 24 μg/mL 이상, 26 μg/mL 이상, 28 μg/mL 이상 또는 30 μg/mL 이상일 수 있다. 또한, 상기 실리마린의 용출 농도는, 31 μg/mL 이하, 28.5 μg/mL 이하, 25.5 μg/mL 이하 또는 22 μg/mL 이하일 수 있다. 바람직하게는, 상기 실리마린의 용출 농도는 19.6 내지 31 μg/mL일 수 있다.In one embodiment, the food composition is measured by dissolution test in purified water according to the paddle method of the dissolution test method based on the Korean Pharmacopoeia, specifically, when measured by rotating at 37°C at a rotation speed of 150 rpm using 500 ml of purified water as an eluate, The elution concentration of silymarin may be 6 to 31 μg/mL within 240 minutes. In another embodiment, the elution concentration of silymarin is 6 μg/mL or more, 6.5 μg/mL or more, 7 μg/mL or more, 8 μg/mL or more, 8.5 μg/mL or more, 9 μg/mL or more, 9.5 μg/mL or higher, 15 μg/mL or higher, 19 μg/mL or higher, 19.6 μg/mL or higher, 23 μg/mL or higher, 24 μg/mL or higher, 26 μg/mL or higher, 28 μg/mL or higher, or 30 μg/mL It can be more than that. In addition, the elution concentration of silymarin may be 31 μg/mL or less, 28.5 μg/mL or less, 25.5 μg/mL or less, or 22 μg/mL or less. Preferably, the elution concentration of silymarin may be 19.6 to 31 μg/mL.
일 구현 예에 따르면, 본 발명에 따른 식품 조성물은 건강 기능 식품 조성물일 수 있으며, 간 기능 개선 용도로 사용될 수 있다.According to one embodiment, the food composition according to the present invention may be a health functional food composition, and may be used for improving liver function.
이때, "개선"이란 증상의 치료, 경감, 예방을 포함하는 의미로서, 본 발명에서는 간 기능, 간 상태, 간 질환, 간 질병이 치료, 경감 또는 예방되는 것을 말한다.At this time, "improvement" refers to treatment, alleviation, and prevention of symptoms, and in the present invention, it refers to treatment, alleviation or prevention of liver function, liver condition, liver disease, and liver disease.
본 발명에서, "예방"은 본 발명에 따른 조성물의 투여로 간 질환의 발병을 억제 또는 지연시키는 모든 행위를 말한다.In the present invention, "prevention" refers to any action of inhibiting or delaying the onset of liver disease by administration of the composition according to the present invention.
본 발명에서 "간 질환"이란 본 발명의 조성물에 의해 치료, 경감 또는 예방될 수 있는 간 질환은 제한 없이 포함되나, 그 예로 비알콜성 지방간, 알코올성 지방간, 간염, 간경화, 간암 등이 있을 수 있다.In the present invention, "liver disease" includes, without limitation, liver diseases that can be treated, alleviated or prevented by the composition of the present invention, examples of which may include non-alcoholic fatty liver, alcoholic fatty liver, hepatitis, cirrhosis, liver cancer, etc. .
본 발명의 건강기능식품 조성물은 본 발명의 효과를 해치지 않는 범위 안에서 영양보급 효과를 위한 부원료와 관능성 개선 및 제형 형성을 위한 첨가제를 포함할 수 있다.The health functional food composition of the present invention may include an additive for nutritional replenishment effect and an additive for improving organoleptic properties and formulation formation within a range that does not impair the effect of the present invention.
이하, 본 발명의 내용을 실시예 및 시험예를 통하여 보다 구체적으로 설명한다. 그러나, 이러한 실시예 및 시험예는 본 발명의 내용을 이해하기 위해 제시되는 것일 뿐, 본 발명의 권리범위가 이러한 실시예 및 시험예로 한정되는 것은 아니고, 당업계에서 통상적으로 주지된 변형, 치환 및 삽입 등을 수행할 수 있으며, 이에 대한 것도 본 발명의 범위에 포함된다.Hereinafter, the content of the present invention will be described in more detail through Examples and Test Examples. However, these examples and test examples are only presented to understand the content of the present invention, and the scope of the present invention is not limited to these examples and test examples, and modifications and substitutions commonly known in the art And insertion and the like can be performed, and this is also included in the scope of the present invention.
[실시예 및 비교예][Examples and Comparative Examples]
하기 표 1(단위: mg)의 조성에 따라 총 함량 600mg의 조성물인 실시예 1 내지 21 및 비교예 1 내지 4를 제조하였다.According to the composition of Table 1 (unit: mg), Examples 1 to 21 and Comparative Examples 1 to 4, which are compositions having a total content of 600 mg, were prepared.
콜린Phosphatidyl
Choline
: 포스파티딜콜린 및 대두레시틴 중 하나 이상
(중량비)Silymarin
: At least one of phosphatidylcholine and soybean lecithin
(Weight ratio)
1Comparative example
One
2Comparative example
2
3Comparative example
3
4Comparative example
4
1Example
One
2Example
2
3Example
3
4Example
4
5Example
5
6Example
6
7Example
7
8Example
8
9Example
9
10Example
10
11Example
11
12Example
12
13Example
13
14Example
14
15Example
15
16Example
16
17Example
17
18Example
18
19Example
19
20Example
20
21Example
21
[실험예 1] 실리마린 용출 평가 실험[Experimental Example 1] Silymarin dissolution evaluation experiment
상기 실시예 1 내지 21, 비교예 1 내지 4 및 밀크씨슬 추출물의 용출율을 비교 평가하였다. 밀크씨슬 추출물은 밀크씨슬(흰무늬엉겅퀴)을 주정 추출한 후 여과, 농축 및 정제하여 제조한 원료로서 실리마린의 함량이 50%인 밀크씨슬 추출물(HONSON INGREDIENTS 社, 캐나다)을 사용하였다.The dissolution rates of Examples 1 to 21, Comparative Examples 1 to 4, and milk thistle extract were compared and evaluated. Milk thistle extract is a raw material prepared by filtration, concentration and purification after extracting milk thistle (white patterned thistle) with alcohol, and milk thistle extract (HONSON INGREDIENTS, Canada) containing 50% silymarin was used.
용출 평가 시험은, 대한민국약전에 의한 용출시험법으로 in vitro 용출을 평가하였으며, HPLC 분석법으로 실리마린의 대표 성분인 실리빈(silybin) 함량을 정량하여 평가하였다. 구체적으로, 대한민국약전에 의한 용출시험항목의 패들법에 따라 상기 실시예 1 내지 21, 비교예 1 내지 4 및 밀크씨슬 추출물을 각각 3ml씩 취하여 정제수 500ml를 용출액으로 하여 37℃의 온도에서 회전수 150rpm으로 하여 측정하였다. 그 결과는 하기 표 2(단위: μg/mL) 및 도 1에 나타내었다.In the dissolution evaluation test, in vitro dissolution was evaluated by the dissolution test method of the Korean Pharmacopoeia, and the content of silybin, a representative component of silymarin, was quantified and evaluated by HPLC analysis. Specifically, according to the paddle method of the dissolution test item by the Korean Pharmacopoeia, 3 ml of each of Examples 1 to 21, Comparative Examples 1 to 4, and milk thistle extract were taken, and 500 ml of purified water was used as the eluent at a temperature of 37°C It was measured at 150 rpm. The results are shown in Table 2 (unit: μg/mL) and FIG. 1 below.
추출물Milk Thistle
extract
1Comparative example
One
2Comparative example
2
3Comparative example
3
4Comparative example
4
1Example
One
2Example
2
3Example
3
4Example
4
5Example
5
6Example
6
7Example
7
8Example
8
9Example
9
10Example
10
11Example
11
12Example
12
13Example
13
14Example
14
15Example
15
16Example
16
17Example
17
18Example
18
19Example
19
20Example
20
21Example
21
표 2 및 도 1의 결과로부터, 실리마린과 대두유만을 포함하는 비교예 1에 비하여, 실리마린, 대두유, 및 레시틴 및 포스파티딜콜린 중 하나 이상을 포함하는 실시예 1 내지 21의 경우 실리마린의 용출 농도가 보다 높은 것으로 나타나, 레시틴 및 포스파티딜콜린 중 하나 이상을 포함함으로써 실리마린의 용출율이 높아짐을 확인할 수 있었다.From the results of Table 2 and Fig. 1, compared to Comparative Example 1 containing only silymarin and soybean oil, in Examples 1 to 21 containing at least one of silymarin, soybean oil, and lecithin and phosphatidylcholine, the elution concentration of silymarin was higher. As a result, it was confirmed that the dissolution rate of silymarin was increased by including at least one of lecithin and phosphatidylcholine.
또한, 실리마린과 레시틴 및 포스파티딜콜린 중 하나 이상을 1:0.46 내지 1:1.53의 중량비로 포함하는 실시예 7 내지 21의 경우에는 용출 시험 240분 경과 시 실리마린의 용출 농도가 밀크시슬 추출물에 비해서도 크게 높아지는 것을 확인할 수 있었다.In addition, in the case of Examples 7 to 21 containing at least one of silymarin, lecithin, and phosphatidylcholine in a weight ratio of 1:0.46 to 1:1.53, the elution concentration of silymarin was significantly increased compared to the milk thistle extract after 240 minutes of the dissolution test. I could confirm.
즉, 본 발명에 따른 실리마린의 생체이용률 향상용 첨가제 조성물과 실리마린을 포함하는 건강 기능 식품 조성물은 밀크씨슬 추출물을 단독으로 섭취하는 경우에 비하여 실리마린의 우수한 용출율에 의해 생체이용률이 크게 향상될 수 있음을 확인할 수 있었다.That is, the bioavailability improvement additive composition of silymarin and the health functional food composition comprising silymarin according to the present invention can significantly improve the bioavailability due to the superior dissolution rate of silymarin compared to when the milk thistle extract is consumed alone. Could be confirmed.
한편, 비교예 2 내지 4의 경우에는 레시틴 및 포스파티딜콜린 중 하나 이상의 함량이 높아짐에 따라 실리마린의 용출 농도도 높아지는 것을 확인할 수 있었으나, 아래 실험예 2에서 살펴볼 바와 같이, 붕해 시험 결과 연질캡슐로의 제형화가 불가능한 것을 확인할 수 있었다.On the other hand, in the case of Comparative Examples 2 to 4, it was confirmed that the elution concentration of silymarin increased as the content of one or more of lecithin and phosphatidylcholine increased, but as shown in Experimental Example 2 below, as a result of the disintegration test, formulation into a soft capsule I could see what was impossible.
[실험예 2] 연질캡슐 제형의 붕해 시험[Experimental Example 2] Disintegration test of soft capsule formulation
상기 실시예 11 및 비교예 2의 조성물이 연질 캡슐 제형으로의 생산이 적합한지 여부를 평가하기 위하여 붕해 시험을 진행하였다. 붕해 시험은 식품공전 일반시험법 중 붕해시험법에 따라 진행하였다. 구체적으로, 물을 시험액으로 하여 붕해도 시험기(J-DTC2, JISICO 社)를 사용하여 수행하였다. 연질 캡슐의 경우 20분 내에 붕해가 완료되어야 하며, 보조판을 넣고 20분 간 상하운동을 시킨 다음 각 조성물의 잔류물이 유리관 내에 없거나 있더라도 피막일 경우에는 붕해가 완료된 것으로 판단하였다.A disintegration test was conducted to evaluate whether the compositions of Example 11 and Comparative Example 2 were suitable for production in a soft capsule formulation. The disintegration test was conducted according to the disintegration test method among general test methods of the food code. Specifically, water was used as a test solution, and a disintegration tester (J-DTC2, JISICO) was used. In the case of soft capsules, disintegration should be completed within 20 minutes, and after placing the auxiliary plate and performing vertical motion for 20 minutes, it was judged that the disintegration was completed in the case of a film even if the residue of each composition was not in the glass tube.
그 결과는 도 2에 나타내었다. 도 2의 결과로부터, 본 발명에 따른 실시예 11의 조성물의 경우, 20분 안에 붕해가 완전히 이루어져 연질 캡슐로의 생산이 적합함을 확인할 수 있었다. 반면, 비교예 2의 경우, 실리마린과 레시틴 및 포스파티딜콜린 중 하나 이상의 중량비가 1:2.31로서, 레시틴, 포스파티딜콜린의 함량이 지나치게 많아 점도가 높아짐으로 인하여 20분 내에 붕해가 완료되지 않으며, 따라서 연질 캡슐로의 생산이 부적합함을 확인할 수 있었다.The results are shown in FIG. 2. From the results of Figure 2, in the case of the composition of Example 11 according to the present invention, it was confirmed that the disintegration was completely completed within 20 minutes, so that the production into a soft capsule is suitable. On the other hand, in the case of Comparative Example 2, the weight ratio of at least one of silymarin, lecithin, and phosphatidylcholine is 1:2.31, and the content of lecithin and phosphatidylcholine is too high, so that the disintegration is not completed within 20 minutes due to the high viscosity. It could be confirmed that the production was inappropriate.
[실험예 3] 생체이용률 평가 실험[Experimental Example 3] Bioavailability Evaluation Experiment
상기 실험예 1의 밀크씨슬 추출물, 및 실시예 11의 조성물 각각의 약물 동력학을 조사하여 실리마린의 주성분인 실리빈의 생체이용률을 평가하였다. 구체적으로, 5마리의 SD랫트에 각각 밀크씨슬 추출물 및 실시예 11의 조성물을 실리빈 농도를 기준으로 200mg/kg씩 경구 투여한 다음, 시간 경과에 따라 총 11회(0분, 2분, 5분, 10분, 20분, 30분, 45분, 60분, 90분, 120분, 180분) 채혈하여 혈장 내 실리빈 농도를 고성능 액체 크로마토그래피(high performance liquid chromatography, HPLC)로 분석하였다.The pharmacokinetics of the milk thistle extract of Experimental Example 1 and the composition of Example 11 were investigated to evaluate the bioavailability of silybin, which is the main component of silymarin. Specifically, the milk thistle extract and the composition of Example 11 were orally administered to 5 SD rats at 200 mg/kg based on the silybin concentration, followed by a total of 11 times (0 min, 2 min, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes, 120 minutes, 180 minutes) blood was collected and the concentration of silybin in plasma was analyzed by high performance liquid chromatography (HPLC). .
HPLC 분석 조건은 아래와 같다.HPLC analysis conditions are as follows.
-HPLC 모델: Shimadzu HPLC-UV system Prominence model-HPLC model: Shimadzu HPLC-UV system Prominence model
-분석 컬럼: Kientex C18 Column (250 × 4.6mm)-Analytical column: Kientex C18 Column (250 × 4.6mm)
-이동상: Isocratic mode, 10 mM Ammonium acetate buffer : Acetonitrile = 74 : 26-Mobile phase: Isocratic mode, 10 mM Ammonium acetate buffer: Acetonitrile = 74: 26
-유속: 1.0 mL/min-Flow rate: 1.0 mL/min
-UV 파장: 288 nm-UV wavelength: 288 nm
-샘플 주입 부피: 20 μL-Sample injection volume: 20 μL
HPLC 분석 방법은, 구체적으로, SD랫트의 혈장 120μL를 취하여, 내부 표준물질(Phenacetin 3 μg/mL)이 포함된 Acetonitrile 400μL를 넣고 5분 동안 혼합하여 제단백을 하였다. 그 후 제단백한 샘플을 10분 간 4℃에서 15,000xg로 원심 분리하여 상등액 400μL를 취한 후, 이를 질소 농축기를 이용하여 건조한 다음, 60μL의 이동상으로 재구축 하였다. 그 후 샘플 20μL를 HPLC에 주입하여 분석하였다.In the HPLC analysis method, specifically, 120 μL of plasma from SD rats was taken, 400 μL of Acetonitrile containing an internal standard (
그 결과는 하기 표 3 및 도 3에 나타내었다.The results are shown in Table 3 and FIG. 3 below.
(AUClast는 실험약물의 혈중 전체 흡수량을 비교하는 지표를 나타내며, Cmax는 실험약물의 혈중 최고 농도 지표를 나타낸다.)(AUC last represents an index that compares the total absorption of the test drug in the blood, and C max represents the index of the highest concentration in the blood of the test drug.)
표 3 및 도 3의 결과로부터, 본 발명에 따른 실시예 11의 조성물의 경우, 밀크씨슬 추출물에 비하여 실리마린의 주성분인 실리빈의 혈중 전체 흡수량 및 혈중 최고 농도 값이 모두 크게 증가한 것을 확인할 수 있었다. 즉, 본 발명에 따른 실시예 11의 경우, 실리마린의 생체이용률이 밀크씨슬 추출물에 비하여 현저히 높은 것을 확인할 수 있었다.From the results of Table 3 and FIG. 3, in the case of the composition of Example 11 according to the present invention, it was confirmed that both the total blood absorption of silybin, the main component of silymarin, and the highest blood concentration value in the blood were significantly increased compared to the milk thistle extract. . That is, in the case of Example 11 according to the present invention, it was confirmed that the bioavailability of silymarin was significantly higher than that of the milk thistle extract.
Claims (12)
레시틴(lecithin) 및 포스파티딜콜린(phosphatidylcholine) 중 하나 이상을 유효성분으로 함유하며,
실리마린 및 식물성 오일을 포함하는 식품 조성물에 첨가되고,
상기 실리마린 : 레시틴 및 포스파티딜콜린 중 하나 이상의 중량비가 1:0.08 이상 및 1:2.31 미만이 되도록 상기 식품 조성물에 첨가되는, 실리마린의 생체이용률 향상용 첨가제 조성물.As an additive composition for improving the bioavailability of silymarin,
It contains at least one of lecithin and phosphatidylcholine as an active ingredient,
It is added to a food composition comprising silymarin and vegetable oil,
The silymarin: an additive composition for improving the bioavailability of silymarin, which is added to the food composition such that a weight ratio of at least one of lecithin and phosphatidylcholine is 1:0.08 or more and 1:2.31 or less.
상기 실리마린은 밀크씨슬(milk thistle) 추출물로부터 얻은 것임을 특징으로 하는, 실리마린의 생체이용률 향상용 첨가제 조성물.The method of claim 1,
The silymarin is an additive composition for improving the bioavailability of silymarin, characterized in that obtained from milk thistle extract.
상기 레시틴은 대두레시틴 및 난황레시틴 중 하나 이상인 것을 특징으로 하는, 실리마린의 생체이용률 향상용 첨가제 조성물.The method of claim 1,
The lecithin is an additive composition for improving bioavailability of silymarin, characterized in that at least one of soybean lecithin and yolk lecithin.
상기 식물성 오일은 대두유, 해바라기유, 유채씨유, 아보카도유, 옥수수유, 팜유, 야자유, 현미유, 목화씨유, 피마자유, 참깨씨유, 아마씨유, 올리브유, 카놀라유, 포도씨유, 아몬드유, 땅콩유, 헤이즐넛유 및 호두유 중에서 선택된 하나 이상인 것을 특징으로 하는, 실리마린의 생체이용률 향상용 첨가제 조성물.The method of claim 1,
The vegetable oils are soybean oil, sunflower oil, rapeseed oil, avocado oil, corn oil, palm oil, palm oil, brown rice oil, cottonseed oil, castor oil, sesame seed oil, flaxseed oil, olive oil, canola oil, grapeseed oil, almond oil, peanut oil , An additive composition for improving bioavailability of silymarin, characterized in that at least one selected from hazelnut oil and walnut oil.
상기 실리마린 : 레시틴 및 포스파티딜콜린 중 하나 이상의 중량비가 1:0.46 내지 1:1.53인 것을 특징으로 하는, 실리마린의 생체이용률 향상용 첨가제 조성물.The method of claim 1,
The silymarin: an additive composition for improving bioavailability of silymarin, characterized in that the weight ratio of at least one of lecithin and phosphatidylcholine is 1:0.46 to 1:1.53.
상기 식품 조성물은 점도가 1800 cps 미만인 것을 특징으로 하는, 실리마린의 생체이용률 향상용 첨가제 조성물.The method of claim 1,
The food composition is characterized in that the viscosity is less than 1800 cps, an additive composition for improving the bioavailability of silymarin.
레시틴(lecithin) 및 포스파티딜콜린(phosphatidylcholine) 중 하나 이상을 유효성분으로 함유하며,
실리마린 및 식물성 오일을 포함하는 식품 조성물에 첨가되고,
상기 식품 조성물은 대한민국약전에 의거한 용출시험법의 패들법에 따라 정제수에서 용출 시험 시, 240분 이내에 실리마린의 용출 농도가 6 내지 31 μg/mL인, 실리마린의 생체이용률 향상용 첨가제 조성물.As an additive composition for improving the bioavailability of silymarin,
It contains at least one of lecithin and phosphatidylcholine as an active ingredient,
It is added to a food composition comprising silymarin and vegetable oil,
The food composition is an additive composition for improving the bioavailability of silymarin, wherein the elution concentration of silymarin is 6 to 31 μg/mL within 240 minutes when dissolution test in purified water according to the paddle method of the dissolution test method based on the Korean Pharmacopoeia.
상기 실리마린의 용출 농도가 19.6 내지 31 μg/mL인 것을 특징으로 하는, 실리마린의 생체이용률 향상용 첨가제 조성물.The method of claim 7,
An additive composition for improving bioavailability of silymarin, characterized in that the elution concentration of silymarin is 19.6 to 31 μg/mL.
상기 실리마린 : 레시틴 및 포스파티딜콜린 중 하나 이상의 중량비가 1:0.08 이상 및 1:2.31 미만이 되도록 상기 식품 조성물에 첨가되는 것을 특징으로 하는, 실리마린의 생체이용률 향상용 첨가제 조성물.The method of claim 7,
The silymarin: an additive composition for improving the bioavailability of silymarin, characterized in that it is added to the food composition so that the weight ratio of at least one of lecithin and phosphatidylcholine is 1:0.08 or more and 1:2.31 or less.
상기 식품 조성물은 연질캡슐 제형인 것을 특징으로 하는, 실리마린의 생체이용률 향상용 첨가제 조성물.The method according to any one of claims 1 to 9,
The food composition is an additive composition for improving the bioavailability of silymarin, characterized in that the soft capsule formulation.
상기 식품 조성물은 연질캡슐 제형인 것을 특징으로 하는, 식품 조성물.The method of claim 11,
The food composition is characterized in that the soft capsule formulation, food composition.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190033602A KR102394648B1 (en) | 2019-03-25 | 2019-03-25 | Composition for enhancing bioavailability of silymarin |
SG10201910593RA SG10201910593RA (en) | 2019-03-25 | 2019-11-13 | Composition for enhancing bioavailability of silymarin |
CN201911264420.XA CN111728209A (en) | 2019-03-25 | 2019-12-11 | Composition for enhancing bioavailability of silymarin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190033602A KR102394648B1 (en) | 2019-03-25 | 2019-03-25 | Composition for enhancing bioavailability of silymarin |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20200113429A true KR20200113429A (en) | 2020-10-07 |
KR102394648B1 KR102394648B1 (en) | 2022-05-09 |
Family
ID=72645658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190033602A KR102394648B1 (en) | 2019-03-25 | 2019-03-25 | Composition for enhancing bioavailability of silymarin |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR102394648B1 (en) |
CN (1) | CN111728209A (en) |
SG (1) | SG10201910593RA (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116650386B (en) * | 2023-07-18 | 2024-02-02 | 广州市百集生物科技有限公司 | Composition for whitening human body and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050075074A (en) | 2004-01-15 | 2005-07-20 | 한국유나이티드제약 주식회사 | Silymarin-containing pharmaceutical composition and soft capsules containing the same |
KR20140071913A (en) * | 2012-12-04 | 2014-06-12 | 삼성정밀화학 주식회사 | Food composition and soft capsule including the same |
KR20170026240A (en) * | 2015-08-28 | 2017-03-08 | 김병용 | Health functional food composition for improving liver function |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100342942B1 (en) * | 1999-07-05 | 2002-07-02 | 민경윤 | Oral micro-emulsion composition comprising Carduus marianus extract or silybin isolated therefrom |
CN1233318C (en) * | 2004-07-08 | 2005-12-28 | 上海交通大学 | Hepadestal soft capsule and its preparing method |
CN100594898C (en) * | 2005-11-11 | 2010-03-24 | 天津天士力制药股份有限公司 | Pharmaceutical composition of Silybin and preparation method thereof |
CN101112364A (en) * | 2006-07-28 | 2008-01-30 | 天津天士力制药股份有限公司 | Hepadestal preparations and method for preparing the same |
CN101342167B (en) * | 2007-07-10 | 2012-03-21 | 陈亚玲 | Medicament composition |
CN101143142A (en) * | 2007-08-23 | 2008-03-19 | 沈阳万爱普利德医药科技有限公司 | Silybin supersaturated self-emulsion composition and preparation method thereof |
CN101513393A (en) * | 2008-02-22 | 2009-08-26 | 石药集团恩必普药业有限公司 | Silymarin soft capsule and method for preparing same |
CN103751799A (en) * | 2014-01-27 | 2014-04-30 | 江苏健佳药业有限公司 | Phospholipid complex of silybum marianum extract and preparation method for phospholipid complex |
-
2019
- 2019-03-25 KR KR1020190033602A patent/KR102394648B1/en active IP Right Grant
- 2019-11-13 SG SG10201910593RA patent/SG10201910593RA/en unknown
- 2019-12-11 CN CN201911264420.XA patent/CN111728209A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050075074A (en) | 2004-01-15 | 2005-07-20 | 한국유나이티드제약 주식회사 | Silymarin-containing pharmaceutical composition and soft capsules containing the same |
KR20140071913A (en) * | 2012-12-04 | 2014-06-12 | 삼성정밀화학 주식회사 | Food composition and soft capsule including the same |
KR20170026240A (en) * | 2015-08-28 | 2017-03-08 | 김병용 | Health functional food composition for improving liver function |
Also Published As
Publication number | Publication date |
---|---|
SG10201910593RA (en) | 2020-10-29 |
CN111728209A (en) | 2020-10-02 |
KR102394648B1 (en) | 2022-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Abenavoli et al. | Milk thistle in liver diseases: past, present, future | |
EP0925068B1 (en) | Use of a pharmaceutical composition containing polyphenols from grapes or from wine, in particular resveratrol, and yeast extracts | |
JP4598740B2 (en) | Glutathione enhancing composition | |
JP7490557B2 (en) | Compositions containing berberine | |
JP5275251B2 (en) | Composition comprising an extract of a combined herb for preventing and treating liver disease | |
JP2010513473A5 (en) | ||
KR101523586B1 (en) | Pharmaceutical composition for preventing or treating prostatic hyperplasia and preparation method thereof | |
JP2006348052A (en) | Composition for enhancing glutathione | |
KR102394648B1 (en) | Composition for enhancing bioavailability of silymarin | |
KR20100067299A (en) | Composition for inhibiting obesity comprising mixture of herbal mixture extract of ephedrae herba,gypsum and atractylis chinensis and extract of green tea as an active ingredient | |
KR101144715B1 (en) | The oral medication for increasing of sperm numbers | |
KR102062773B1 (en) | A pharmaceutical composition for treating or preventing alcoholic liver disease comprising ormosanine as an active ingredient | |
CN103127235B (en) | Preparation method of medicine having liver protection and liver fibrosis effects | |
KR101469201B1 (en) | A COMPOSITION COMPRISING EXTRACT OF Laminaria japonica OR PORPYRIN-RELATED COMPOUNDS ISOLATED THEREFROM PREVENTING OR TREATING DIABETIC COMPLICATION | |
KR20140026737A (en) | A composition comprising the powder of fermented curcuma longa l. for protecting alcoholic liver damage | |
KR100818091B1 (en) | Pharmaceutical oral composition containing flavonolignans using auto micellization drug delivery system | |
US20120201903A1 (en) | Cytoprotective or therapeutic plant composition | |
KR101469961B1 (en) | Method for separating porpyrin-related compounds from laminaria japonica for use in the prevention or treatment of diabetic complication | |
KR101026524B1 (en) | A medicinal herbs composition for protective stomach and intestines | |
CN107281230A (en) | A kind of pharmaceutical composition and preparation method thereof and the application in the medicine for preparing treatment hypertension | |
JP2007161667A (en) | Composition, medicine and functional food for inhibiting blood glucose level elevation | |
KR20190045073A (en) | Dietary herbal composition for improving obesity and method for producing the same | |
CN1593431A (en) | Pharmaceutical composition for protecting liver | |
EP1498131A1 (en) | Medicinal preparation containing phenylethanoid glycosides extracted from Cistanche tubulosa | |
KR101543998B1 (en) | Composition for treating and improving fatty liver and hyperlipidemia comprising extract of olive as an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |